Pentwater and Halbower File Schedule 13G for 5.2% of AMED

Rhea-AI Filing Summary

Amedisys Inc. Schedule 13G shows Pentwater Capital Management LP and Matthew Halbower disclose beneficial ownership of 1,715,084 shares of Amedisys common stock, representing 5.2% of the class based on 32,819,638 shares outstanding as of April 25, 2025. The shares are held directly by the Pentwater Funds with Pentwater acting as investment manager; Mr. Halbower is disclosed as the sole shareholder of the general partner of the manager. The filing states the position is held in the ordinary course of business and not to influence control. Signatures dated 08/14/2025 accompany a joint filing agreement.

Positive

• Material ownership disclosed: Reporting Persons hold 1,715,084 shares representing 5.2% of AMED, exceeding the 5% reporting threshold.
• Clear identification: The filing names Pentwater Capital Management LP and Matthew Halbower and provides business addresses and citizenship.
• Ordinary-course assertion: The securities are stated to be held in the ordinary course of business, not for control purposes, which clarifies intent in this filing.

Negative

• No sole voting or dispositive power: All authority is shared (1,715,084 shares), indicating no unilateral control from the reporting parties.

Insights

Financial Analyst

TL;DR: A 5.2% passive stake by an activist-capable manager merits monitoring for potential engagement or influence.

Pentwater's 5.2% holding is material for investors because it exceeds the 5% disclosure threshold and signals a notable position size in Amedisys (AMED). The filing characterizes the stake as held in the ordinary course of business, which suggests no current intent to influence control; however, Pentwater is an investment manager with the capacity to aggregate positions across its funds. The shared voting and dispositive power indicates control is exercised collectively through the Pentwater Funds rather than by an individual. Market participants should note the ownership base and the manager identity when assessing potential shareholder engagement or future proposals.

Corporate Governance Expert

TL;DR: Disclosure complies with Schedule 13G mechanics but provides limited governance signaling beyond ownership size.

The filing properly identifies the reporting persons, the ownership percentage, and the nature of voting and dispositive power. Classification of the position as held in the ordinary course of business reduces immediate governance alarm but does not preclude future action; the joint filing agreement and signatures are in place. The absence of sole voting power and the pooled structure of the funds mean direct unilateral control is unlikely from this filing alone.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMEDISYS INC

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

023436108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 023436108

1

Names of Reporting Persons

Pentwater Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,715,084.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,715,084.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,715,084.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 023436108

1

Names of Reporting Persons

Matthew Halbower

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,715,084.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,715,084.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,715,084.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AMEDISYS INC
(b)	Address of issuer's principal executive offices: 3854 American Way, Suite A Baton Rouge, LA 70816
Item 2.
(a)	Name of person filing: (i) Pentwater Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to certain funds (the "Pentwater Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock") of Amedisys, Inc., a Delaware corporation (the "Company") directly held by the Pentwater Funds; and (ii) Mr. Matthew Halbower ("Mr. Halbower"), the sole shareholder of MCH PWCM Holdings Inc., the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Pentwater Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 1001 10th Avenue South, Suite 216, Naples, FL 34102.
(c)	Citizenship: The Investment Manager is a Delaware limited partnership. Mr. Halbower is a citizen of the United States.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 023436108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 32,819,638 shares of Common Stock outstanding as of April 25, 2025, as reported in Amendment No. 2 to the Company's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on April 29, 2025.
(b)	Percent of class: 5.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Pentwater Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pentwater Capital Management LP

Signature:	/s/ Matthew Halbower
Name/Title:	By: MCH PWCM Holdings Inc., General Partner, By: Matthew Halbower, Chief Executive Officer
Date:	08/14/2025

Matthew Halbower

Signature:	/s/ Matthew Halbower
Name/Title:	Matthew Halbower, Individually
Date:	08/14/2025

Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake in Amedisys (AMED) do Pentwater and Matthew Halbower report?

They report beneficial ownership of 1,715,084 shares, representing 5.2% of AMED based on 32,819,638 shares outstanding as of April 25, 2025.

Who exactly filed the Schedule 13G for AMED?

The filing was made jointly by Pentwater Capital Management LP (the investment manager) and Matthew Halbower (sole shareholder of the general partner).

Does the filing indicate Pentwater seeks to change control of Amedisys?

No. The certification states the shares are held in the ordinary course of business and were not acquired to change or influence control.

What type of voting and dispositive power do the reporting persons have?

The reporting persons report 0 sole voting power and 1,715,084 shared voting power, and similarly 0 sole and 1,715,084 shared dispositive power.

When was the Schedule 13G signed?

Signatures on the filing are dated 08/14/2025 and include a joint filing agreement (Exhibit 99.1).